Prophylaxis of Influenza (Northern Hemispher 2021-2022 and 2022-2023 season) in Children aged 6-8 months
Conditions
Interventions
Trade Name: Vaxigrip Tetra®
Product Name: Quadrivalent Influenza Vaccine(split-virion, inactivated)
Pharmaceutical Form: Suspension for injection in pre-filled syringe
INN or Proposed INN: INFLUENZA V
Sponsors
Université Libre de Bruxelles
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male or female infants born at = 36 weeks of gestation and aged 6 to 8 months Provide written informed consent from parents. The parents are willing to comply with study protocol requirements, including availability for all scheduled visits of the study. Subjects are healthy or with well-controlled pre-existing medical conditions by the opinion of the investigator Are the trial subjects under 18? yes Number of subjects for this age range: 50 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Acute illness, at the time of study vaccine administration (once acute illness is resolved, if appropriate, as per investigator assessment, participant will be re-revaluated for eligibility). 2. Recorded fever (for eligibility purpose defined as a body temperature greater than 37.5°C) within 3 days prior to study vaccine administration (once fever/acute illness is resolved, if appropriate, as per investigator assessment, participant will be re-evaluated for eligibility. 3. Current or previous, laboratory confirmed case of influenza during the past 6 months, based on anamnesis or medical file (if available) at screening visit 4. Household contact with and/or intimate exposure to an individual with any laboratory confirmed influenza infection during the past 6 months prior to vaccination. 5. History of severe allergic reactions after previous vaccinations or hypersensitivity to any study vaccine component 6. Previous history of Guillain Barre Syndrome. 7. Any confirmed or suspected condition with impaired/altered function of immune system (e.g. immunodeficient or autoimmune conditions). 8. Having tested positive for Human Immuno-deficiency Virus (HIV), Hepatitis B or Hepatitis C 9. Having any bleeding disorder which is considered as a contraindication to intramuscular injection or blood draw according to the opinion of the investigator 10. Chronic administration (defined as more than 14 days) of immunosuppressant or other immune-modifying drugs within three months prior to the study vaccination or planned use throughout the study period. (For corticosteroids, this means prednisone, or equivalent, = 0.5 mg/kg per day. Inhaled, intranasal and topical steroids are allowed. 11. Administration of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 3 months or planned use throughout the study period.; 12. Administration of any vaccine within 28 days prior to enrolment in the study or planned administration of any vaccine during study participation. 13. Use of any investigational or non-registered drug or vaccine within 30 days prior to the administration of study vaccines or planned during the study. 14. Having received systemic antibiotic treatment within 3 days prior to enrolment. 15. Acute or chronic, clinically significant pulmonary, cardiovascular, metabolic, neurological, hepatic, or renal functional abnormality, as determined by medical history or physical examination if uncontrolled or without appropriate treatment 16. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study or make it unlikely that the participant could complete the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Immunogenicity -To measure the level of immune response [HAI-haemagglutinin Antibody Inhibition titres] of 2 intramuscular doses of the quadrivalent inactivated influenza vaccine (Vaxigrip Tetra®) in healthy participants aged 6 to 8 months;Secondary Objective: •To measure the levels, avidity, biophysical characteristics and functionality of influenza-specific antibodies induced by the vaccine •To measure the functional programming of peripheral blood immune cells (transcriptome and phenotype), the plasma proteome and metabolome before and after vaccination ;Primary end point(s): •HAI antibody titres on D0 and D58 •Proportion of participants with HAI titres = 40 (1/dilution) at D58 •HAI antibody titres fold increase between D0 and D58 •Proportion of participants with Seroconversion (titre < 10 [1/dilution] at D0 and post-vaccination titre = 40 [1/dilution] at D58, or titre = 10 [1/dilution] at D0 and a = 4-fold increase in titre [1/dilution] at D58 •Proportion of high and low responders (HAI titres <40 (1/dilution) at D58) ;Timepoint(s) of evaluation of this end point: D3 and D58 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable | — |
Countries
Belgium
Contacts
Public ContactDr Tessa Goetghebuer
CHU Saint Pierre
Outcome results
None listed